This study is in progress, not accepting new patients
REFOCUS: a First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with ICC and Other Advanced Solid Tumors
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Relay Therapeutics, Inc.
- ID
- NCT04526106
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- About 490 people participating
- Last Updated